Infection activity in travelers and migrants with chronic schistosomiasis
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial looks at how active a long-term schistosomiasis infection is in travelers and migrants. It aims to better understand the infection to help guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic schistosomiasis (infection lasting more than 3 months after last possible exposure), diagnosed by your doctor's usual methods.
- You must sign a consent form (or have a parent or guardian sign if you are a minor).
- You must be at least 5 years old.
- You cannot have taken praziquantel (a drug for schistosomiasis) after your last possible exposure to the parasite.
- You cannot have an acute (recent) infection, meaning your infection must have started more than 3 months ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different schedules of the drug praziquantel to see which works better for treating liver scarring caused by a parasitic infection called schistosomiasis. It aims to improve liver health and prevent complications.
This study aims to identify the types of schistosomiasis (a parasitic infection) in patients in Assiut Governorate. It involves testing urine or stool samples to confirm the infection.
This study looks at female genital schistosomiasis (a parasite infection that can affect the reproductive organs) in women who have moved from sub-Saharan Africa to France. Researchers want to find out how common it is and what symptoms it causes.
This study tests whether giving preventive medicine to people who move or migrate can help control river blindness and lymphatic filariasis. It focuses on children and household heads who have missed past treatment rounds.
This study looks at how well the right side of the heart works with the lungs in people who have a lung condition caused by schistosomiasis (a parasitic infection). It uses an ultrasound of the heart to check this connection. Results may help doctors understand and treat this condition better.
This study tests a new medicine called arpraziquantel to treat schistosomiasis (a disease from parasites in water) in young children aged 2 to 5. It aims to see if giving this treatment in communities where the disease is common is safe and helpful.
Hear when a new Schistosomiasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.